Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

LifeSci Venture Partners

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 27
Average round size
The average size of a deal this fund participated in
Portfolio companies 22
Rounds per year 5.40
Lead investments 1
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 6
Key employees 3
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical

Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Cala Health, Orasis Pharmaceuticals, Biolinq Among the most successful fund investment fields, there are Clinical Trials, Life Science.

We also calculated 3 valuable employees in our database.

Opposing the other organizations, this LifeSci Venture Partners works on 15 percentage points less the average amount of lead investments. The top amount of exits for fund were in 2019. The fund is generally included in 2-6 deals every year. The common things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 6 percentage points less often commits exit comparing to other organizations. The important activity for fund was in 2019.

The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the LifeSci Venture Partners, startups are often financed by Roche Venture Fund, RiverVest, Novo Ventures. The meaningful sponsors for the fund in investment in the same round are Rock Springs Capital, Redmile Group, Boxer Capital. In the next rounds fund is usually obtained by JDRF T1D Fund, Aphelion Capital.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of LifeSci Venture Partners:
Typical Co-investors
LifeSci Venture Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after LifeSci Venture Partners:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
10x England, London, United Kingdom
Amplifi India, Maharashtra, Mumbai
Barium Capital Kenya, Nairobi, Nairobi Area
Brighton Health Group California, Spring Valley, United States
BTC Investment -
Carao Ventures Costa Rica, San José, San Jose Province
IDB Lab District of Columbia, United States, Washington
Limestone Fund Estonia, Harjumaa, Tallinn
Lundbeckfonden Emerge Copenhagen, Denmark, Hovedstaden
MicroAd Japan, Tokyo
Mitsubishi Hitachi Power Systems Japan, Kanagawa Prefecture, Yokohama
National Bank of Canada | NAventures -
Pocket Ventures Boulder, Colorado, United States
RIDE MEDIA & DESIGN Hokkaido Prefecture, Japan, Meguro
Third Point Ventures New York, New York, United States
Vision Plus Capital China, Hangzhou, Zhejiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

MOMA Therapeutics

$150M10 May 2022 Cambridge, Massachusetts, United States

Beta Bionics

Medical Device
$57M17 Feb 2022 Boston, Massachusetts, United States


$75M19 Jan 2022 New Jersey, United States

Antios Therapeutics

$75M03 Nov 2021 Atlanta, Georgia, United States

Antios Therapeutics

$96M12 Apr 2021 Atlanta, Georgia, United States

Pyxis Oncology

Health Care
$152M30 Mar 2021 Boston, Massachusetts, United States


Data Storage
$24M16 Mar 2021 Carlsbad, California, United States

Caribou Biosciences

Health Care
$115M03 Mar 2021 Berkeley, California, United States


Life Science
$125M02 Mar 2021 Cambridge, Massachusetts, United States
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
– Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
– The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated.
– With over $258m of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.

Antios Therapeutics Raises $96M in a Series B

– Antios Therapeutics from San Diego, CA announced the successful completion of a $96m Series B financing.
– The financing was led by Soleus Capital with participation from new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as other healthcare focused funds, Altium Capital, Amzak Health, Granite Point Capital Management, LP, and LifeSci Venture Partners and participation from all of the original Series A investors including Lumira Ventures, CAM Capital, Delos Capital, Domain Associates and Sixty Degree Capital.
– Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent LifeSci Venture Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: